[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
December 20, 2006

Drug Therapy for Prehypertension Questioned

JAMA. 2006;296(23):2787-2788. doi:10.1001/jama.296.23.2787

Some researchers are questioning a claim made by the authors of a recent study that it is feasible to use drug treatment to reduce the risk that patients with prehypertension will progress to hypertension.

In that study, the Trial of Preventing Hypertension (TROPHY), participants were randomly assigned to receive an angiotensin II receptor blocker, candesartan (AstraZeneca LP, London, England), or placebo for 2 years. All patients were then given placebo and followed up for an additional 2 years (Julius S et al. N Engl J Med. 2006;354:1685-1697).